MDxHealth (MDXH) Registration Filing summary

Company overview and business model

• Commercial-stage precision diagnostics provider focused on non-invasive, cost-effective urologic solutions, primarily for prostate cancer diagnosis and management.

• Core products include Select mdx, Confirm mdx, and Genomic Prostate Score (GPS), all of which offer personalized genomic insights and are included in major U.S. clinical guidelines.

• Over 250,000 tests ordered by more than 7,000 physicians, with a commercial strategy centered on engagement with high-volume urology centers and key physician groups.

• Incorporated in Belgium, with principal executive offices in Herstal, Belgium, and U.S. operations in Irvine, California.

Financial performance and metrics

• As of May 31, 2024: $20.7 million in cash and cash equivalents, $41.3 million in total capitalization, and 27,288,093 shares outstanding.

• Excludes up to 2,243,060 shares underlying new warrants, additional shares from equity programs, and potential earn-out shares.

Use of proceeds and capital allocation

• No proceeds from resale of shares by selling securityholders; proceeds from warrant exercises (if any) will go to the company.

• Company bears registration and listing costs; selling securityholders pay their own commissions and related expenses.